HOME >> BIOLOGY >> NEWS
Carnegie Mellon scientist plays key role in unveiling sea urchin genome

t in their last common ancestor and, conversely, what genes have appeared more recently in the two lineages since they diverged many hundreds of million years ago.

"Having the sea urchin genome is almost an epiphany. I can see the genes, and it's very exciting," added Ettensohn, who has been studying the sea urchin as a model of development for more than 25 years. Specifically, he focuses on the vast network of proteins needed for these animals to form skeletons through biomineralization.

"If we understand how sea urchins build their skeletons, we can learn more about how we build our skeletons," Ettensohn said. "Additionally, understanding how natural systems build skeletons can help us mimic that in the design of materials to treat bone disease and injury in humans."

As part of the Sea Urchin Genome Sequencing Consortium, Ettensohn contributed 51,000 cDNAs -- about one-third of the total genomic material critical for the assembly of the genome and for the accurate prediction of where genes lie within the DNA sequence.

The Ettensohn lab was also one of 15 labs to annotate sets of genes that comprise the sea urchin genome. Initially, computers assembled the genome sequence and predicted the sea urchin genes. These predictions were then verified by scientists in the lab. Ettensohn annotated the genes involved in biomineralization, the process by which sea urchins form their embryonic skeletons. His work resulted in a comprehensive catalog of all the genes that are actually being used by the embryonic cells responsible for building the skeleton, including when and where the genes are expressed in the embryo.

In the sea urchin embryo, specialized cells produce proteins that mix with mineral crystals, thereby regulating the growth and shape of the emerging skeleton, just as in humans. But having the sea urchin genome has revealed a provocative discovery: many of the biomineralization proteins, especially those that control
'"/>

Contact: Lauren Ward
wardle@andrew.cmu.edu
412-268-7761
Carnegie Mellon University
9-Nov-2006


Page: 1 2 3

Related biology news :

1. Carnegie Mellons Peter Adams receives EPA research grant
2. Carnegie Mellon scientists find key HIV protein makes cell membranes bend more easily
3. Carnegie Mellons David Sholl identifies new materials
4. Carnegie Mellon University scientists identify genes activated during learning and memory
5. Carnegie Mellon University research shows how sensory-deprived brain compensates
6. Carnegie Mellon researchers urge regulators to rethink strategies for soot emission
7. Carnegie Mellon researcher proposes development of artificial cells to fight disease
8. Carnegie Mellon engineers devise new process to improve energy efficiency of ethanol production
9. DNA gets new twist: Carnegie Mellon scientists develop unique DNA nanotags
10. Carnegie Mellons Granger Morgan pens op-ed
11. Carnegie Mellon study reveals that odor discrimination is linked to the timing at which neurons fire

Post Your Comments:
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma ... company developing therapeutic products for rare disorders, announced today ... being held in San Francisco, CA. ... and Chief Executive Officer, will present on Monday, January ... The presentation will be webcast live and may be ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: